Vimta Labs posts Q1 FY25consolidated PAT at Rs. 12.28 Cr
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
The inspection closed with five observations which were more of procedural changes with none of these related to data integrity
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols
Shoff brings over 30 years of international experience in in vitro diagnostics, healthcare distribution and veterinary diagnostics
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
The company will address these observations within the stipulated timeline
The company is planning to expand its plant capacity in in Vapi
Subscribe To Our Newsletter & Stay Updated